A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
| Заболевание | Uveal Melanoma |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | Dana-Farber Cancer Institute |
| Статус | Прекращено |
| Участники | 13 участн. |
| Вмешательство | BVD-523 |
| Дата начала | 26.03.2018 |
| Дата завершения | 5.05.2020 |
| Публикация результатов | 11.11.2021 |
Кратко
This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.
Overall Response Rate
| BVD-523 | 0 percentage of participants |
|---|
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)